LPLingyan Ping

Lingyan Ping

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lingyan Ping has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Yuqin Song

    Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing 100142, China

    2 shared publications
  • Hui Yu

    Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing 100142, China

    1 shared publication
  • Jie Chen

    Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing 100142, China

    1 shared publication
  • Jin Chai

    Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing 100142, China

    1 shared publication
  • Jin Chai

    Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma Peking University Cancer Hospital & Institute Beijing China

    1 shared publication
  • Jun Zhu

    Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education) Peking University Cancer Hospital & Institute Beijing China

    1 shared publication

Latest Publications

  • Open Access

    Diagnosis-to-Treatment Interval Reflects Clinical Urgency and Disease Burden in T-Lymphoblastic Lymphoma: A Multicenter Cohort Study

    by Jin Chai, Yunyan Sun, Xuewen Lei, Linjun Zhao, Jie Chen, Wenhui Zhang, Yue Wang, Ni An, Lingyan Ping, Yuqin Song, et al.

    Objective: Diagnosis-to-treatment interval (DTI) has been investigated in several lymphoma subtypes, but its significance in T-lymphoblastic lymphoma (T-LBL) remains unclear. We evaluated whether DTI reflects clinical urgency, disease burden and early outcomes in newly diagnosed T-LBL. Methods: We retrospectively analyzed 220 patients with newly diagnosed, mass-dominant, and histologically diagnosed T-LBL treated at four centers between 2003 and 2025. DTI was operationally defined as the interval from diagnostic biopsy to first systemic anti-lymphoma therapy and was primarily analyzed as a continuous variable per 7-day increase. Descriptive DTI groups were <15, 15–29 and ≥30 days. Results: Median DTI was 20 days (interquartile range [IQR], 14–32). Shorter DTI was associated with advanced stage, elevated lactate dehydrogenase (LDH), multiple extranodal involvement, central nervous system (CNS) involvement, B symptoms, lower hemoglobin and higher International Prognostic Index (IPI) score. CNS involvement remained independently associated with DTI < 15 days. In adjusted analyses, each 7-day increase in DTI was associated with lower odds of early treatment failure within 2 years (odds ratio [OR] 0.72, 95% confidence interval [CI] 0.58–0.88), lower hazards of progression-free survival (PFS) events (hazard ratio [HR] 0.84, 95% CI 0.74–0.94) and lower mortality (HR 0.84, 95% CI 0.73–0.98), but not complete response. Conclusions: Shorter DTI appears to reflect clinical urgency and disease burden rather than a causal effect of early treatment.

  • Open Access

    Clinical Characteristics and Prognosis of Primary Central Nervous System Lymphoma: A Retrospective Analysis

    by Shupeng Zhong, Linjun Zhao, Jin Chai, Lan Mi, Yan Xie, Lingyan Ping, Xiaopei Wang, Jun Zhu, Lijuan Deng, Yuqin Song

    Background: Primary central nervous system lymphoma (PCNSL) is a rare extranodal lymphoma characterized by a poor prognosis due to high relapse rates and a lack of standardized treatment. This study aimed to evaluate the impact of induction/consolidation therapy on long-term survival and to provide extended follow-up data. Methods: In this retrospective analysis, 140 immunocompetent patients with diffuse large B-cell PCNSL (DLBCL-PCNSL) treated at two centers between 2014 and 2024 were enrolled. Treatment efficacy was assessed based on baseline characteristics, therapeutic regimens, and treatment response. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method, and prognostic factors were identified using multivariate Cox proportional hazards regression models. Results: With a median follow-up of 5.3 years (range: 0.1–11.0 years), the 2- and 5-year PFS rates were 50.4% (95% CI: 42.1–60.2) and 34.1% (95% CI: 25.5–45.0), respectively, while the corresponding OS rates were 85.3% (95% CI: 79.4–91.6) and 60.8% (95% CI: 52.0–71.1). No survival plateau was observed. Among patients, 94% received methotrexate-based induction therapy: 94 received rituximab–methotrexate–temozolomide (R-MT) and 17 received MT alone, with 2-year PFS rates of 57.7% and 39.7%, respectively. Overall, 75% of patients achieved remission (CR/CRu/PR) after induction, and among these, 55% underwent consolidation therapy, predominantly autologous stem cell transplantation (ASCT, 90%) or whole-brain radiotherapy (10%). Patients receiving ASCT exhibited superior survival outcomes compared to those who did not. Conclusions: R-MT induction combined with ASCT consolidation is associated with improved survival in PCNSL, although relapse risk remains substantial. Outcomes remain poor in refractory subgroups, highlighting the need for novel therapeutic strategies.